BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dirican A, Varol U, Kucukzeybek Y, Alacacioglu A, Erten C, Somali I, Can A, Demir L, Bayoglu IV, Akyol M, Yildiz Y, Koyuncu B, Coban E, Tarhan MO. Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab? Asian Pac J Cancer Prev. 2014;15:4781-4786. [PMID: 24998541 DOI: 10.7314/apjcp.2014.15.12.4781] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Novillo A, Gaibar M, Romero-Lorca A, Gilsanz MF, Beltrán L, Galán M, Antón B, Malón D, Moreno A, Fernández-Santander A. Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports. World J Gastroenterol 2020;26:1979-86. [PMID: 32390708 DOI: 10.3748/wjg.v26.i16.1979] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Clarke SJ, Burge M, Feeney K, Gibbs P, Jones K, Marx G, Molloy MP, Price T, Reece WHH, Segelov E, Tebbutt NC. The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]. PLoS One 2020;15:e0229900. [PMID: 32142532 DOI: 10.1371/journal.pone.0229900] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
3 Itatani Y, Kawada K, Yamamoto T, Sakai Y. Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway. Int J Mol Sci 2018;19:E1232. [PMID: 29670046 DOI: 10.3390/ijms19041232] [Cited by in Crossref: 64] [Cited by in F6Publishing: 55] [Article Influence: 21.3] [Reference Citation Analysis]
4 Gaibar M, Galán M, Romero-Lorca A, Antón B, Malón D, Moreno A, Fernández-Santander A, Novillo A. Genetic Variants of ANGPT1, CD39, FGF2 and MMP9 Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer. Int J Mol Sci 2021;22:1381. [PMID: 33573134 DOI: 10.3390/ijms22031381] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Dagher M, Sabidó M, Zöllner Y. Effect of age on the effectiveness of the first-line standard of care treatment in patients with metastatic colorectal cancer: systematic review of observational studies. J Cancer Res Clin Oncol 2019;145:2105-14. [PMID: 31201484 DOI: 10.1007/s00432-019-02948-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Botta C, Gullà A, Correale P, Tagliaferri P, Tassone P. Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. Front Oncol. 2014;4:348. [PMID: 25538892 DOI: 10.3389/fonc.2014.00348] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 6.1] [Reference Citation Analysis]
7 Sunakawa Y, Yang D, Cao S, Zhang W, Moran M, Astrow SH, Hsiang J, Stephens C, Tsuji A, Takahashi T, Tanioka H, Negoro Y, Takagane A, Tani S, Yamaguchi T, Eto T, Fujii M, Ichikawa W, Lenz HJ. Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer. Clin Colorectal Cancer 2018;17:e741-9. [PMID: 30219280 DOI: 10.1016/j.clcc.2018.08.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
8 Haibe Y, Kreidieh M, El Hajj H, Khalifeh I, Mukherji D, Temraz S, Shamseddine A. Resistance Mechanisms to Anti-angiogenic Therapies in Cancer. Front Oncol 2020;10:221. [PMID: 32175278 DOI: 10.3389/fonc.2020.00221] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 57.0] [Reference Citation Analysis]
9 Dirican N, Dirican A, Anar C, Atalay S, Ozturk O, Bircan A, Akkaya A, Cakir M. A New Inflammatory Prognostic Index, Based on C-reactive Protein, the Neutrophil to Lymphocyte Ratio and Serum Albumin is Useful for Predicting Prognosis in Non-Small Cell Lung Cancer Cases. Asian Pac J Cancer Prev 2016;17:5101-6. [PMID: 28122441 DOI: 10.22034/APJCP.2016.17.12.5101] [Cited by in F6Publishing: 8] [Reference Citation Analysis]